Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline

Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 pandemic, early signals of efficacy from convalescent plasma therapy have encouraged research and development of anti-SA...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuccori, Marco, Ferraro, Sara, Convertino, Irma, Cappello, Emiliano, Valdiserra, Giulia, Blandizzi, Corrado, Maggi, Fabrizio, Focosi, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755170/
https://www.ncbi.nlm.nih.gov/pubmed/33319649
http://dx.doi.org/10.1080/19420862.2020.1854149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755170/
https://www.ncbi.nlm.nih.gov/pubmed/33319649
http://dx.doi.org/10.1080/19420862.2020.1854149

Ejemplares similares